AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30768188 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal care (delays in antibiotics)
Number of subjects: 568
Study 30768188 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventability of sepsis-associated deaths
Number of subjects: 568
Study 29367653 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic signature derived from pre-therapy imaging using Intensity Direct and Neighbor Intensity Difference methods.
Number of subjects: 465
Study 26434738 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol applied to the entirety of the previous lesion (group A)
Number of subjects: 29
Study 26434738 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol applied only to the remaining lesion (group B)
Number of subjects: 29
Study 25336707 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (6.75 mg bolus, followed by 18 mg/h for 1 hour, then 6 mg/h for 2 hours)
Number of subjects: 800
Study 25336707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v. normal saline)
Number of subjects: 800
Study 22037572 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PRFE device
Number of subjects: 18
Study 22037572 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 18
Study 20551724 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 4
Study 20551724 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/d
Number of subjects: 4
Study 20551724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 18292297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild overnight hypoxia (arterial oxygen saturation approximately 85%)
Number of subjects: 14
Study 18292297 — intervention group
Group type: COMPARATOR
Intervention: Medical air (normoxia)
Number of subjects: 14
Study 15842040 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care monitor (ProTime, International Technidyne Corporation)
Number of subjects: 55
Study 15842040 — intervention group
Group type: COMPARATOR
Intervention: Laboratory INR measurements
Number of subjects: 55
Study 12520569 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 30 mg/kg 30 min before liver resection
Number of subjects: 53
Study 12520569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid administration)
Number of subjects: 53
Study 10383513 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 317
Study 10383513 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 317
Study 8884672 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care supplemented with feedback of patient-reported mental health information
Number of subjects: 573
Study 8884672 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 573
Study 31629334 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic exercise (LIAEX)
Number of subjects: 3
Study 29855069 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-supported sensorimotor training
Number of subjects: 45
Study 29855069 — intervention group
Group type: COMPARATOR
Intervention: Standard splint therapy
Number of subjects: 45
Study 27099480 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent dyadic intervention (home‐based physical exercise training, psycho‐education, communication skills training, and pleasant activities training for 3 months)
Number of subjects: 111
Study 27099480 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 111
Study 24655485 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 27
Study 24655485 — intervention group
Group type: COMPARATOR
Intervention: CHO + BCAA
Number of subjects: 27
Study 24655485 — intervention group
Group type: EXPERIMENTAL
Intervention: PLC
Number of subjects: 27
Study 21540353 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 67
Study 21540353 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (Control)
Number of subjects: 67
Study 21074013 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg buccal misoprostol
Number of subjects: 550
Study 21074013 — intervention group
Group type: COMPARATOR
Intervention: 400 mcg sublingual misoprostol
Number of subjects: 550
Study 21074013 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (buccal and sublingual)
Number of subjects: 550
Study 17621572 — intervention group
Group type: EXPERIMENTAL
Intervention: Acapella device used for airway clearance sessions at home twice daily during oral antibiotic therapy (n=10)
Number of subjects: 20
Study 17621572 — intervention group
Group type: COMPARATOR
Intervention: Usual airway clearance sessions at home during oral antibiotic therapy (n=10)
Number of subjects: 20
Study 17621572 — intervention group
Group type: EXPERIMENTAL
Intervention: Acapella device
Number of subjects: 20
Study 17621572 — intervention group
Group type: COMPARATOR
Intervention: Usual airway clearance
Number of subjects: 20
Study 15618036 — intervention group
Group type: COMPARATOR
Intervention: Left Ventricular (LV) pacing
Number of subjects: 56
Study 15618036 — intervention group
Group type: COMPARATOR
Intervention: Biventricular (BiV) pacing
Number of subjects: 56
Study 15618036 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular (RV) pacing
Number of subjects: 56
Study 12013377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic face stimuli
Number of subjects: 0
Study 12013377 — intervention group
Group type: EXPERIMENTAL
Intervention: Correctly ordered and timed frame stimuli
Number of subjects: 0
Study 12013377 — intervention group
Group type: COMPARATOR
Intervention: Static face stimuli (control)
Number of subjects: 0
Study 9933064 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (Alarm set to void at critical time)
Number of subjects: 125
Study 9933064 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (Alarm to awaken for voiding after 2-3 hours)
Number of subjects: 125
Study 8536677 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) at 900 mg/day or 1200 mg/day
Number of subjects: 0
Study 8536677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2194029 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 360
Study 2194029 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 360
Study 2194029 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 360
Study 2194029 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 360
Study 2194029 — intervention group
Group type: COMPARATOR
Intervention: Atenolol, Captopril, Enalapril
Number of subjects: 360
Study 2194029 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 360
Study 343999 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 40
Study 343999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31724507 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic health coaching for at least 2 years
Number of subjects: 350
Study 31724507 — intervention group
Group type: COMPARATOR
Intervention: Yearly biometric screening (Control)
Number of subjects: 350
Study 31724507 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic health coaching
Number of subjects: 350
Study 29127431 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor cornea with preservation time (PT) of 7 days or less (0-7d PT)
Number of subjects: 1090
Study 29127431 — intervention group
Group type: COMPARATOR
Intervention: Donor cornea with preservation time (PT) of 8 to 14 days (8-14d PT)
Number of subjects: 1090
Study 29127431 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer PT (analyzed as days)
Number of subjects: 1090
Study 29127431 — intervention group
Group type: EXPERIMENTAL
Intervention: PT of 4 days or less
Number of subjects: 1090
Study 29127431 — intervention group
Group type: EXPERIMENTAL
Intervention: PT of 5 to 7 days
Number of subjects: 1090
Study 29127431 — intervention group
Group type: EXPERIMENTAL
Intervention: PT of 8 to 11 days
Number of subjects: 1090
Study 29127431 — intervention group
Group type: EXPERIMENTAL
Intervention: PT of 12 to 14 days
Number of subjects: 1090
Study 25766863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 0
Study 25766863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23325919 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐[1‐(13)C]threonine enterally or parenterally
Number of subjects: 6
Study 23325919 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐[1‐(13)C]lysine enterally or parenterally
Number of subjects: 6
Study 21295881 — intervention group
Group type: EXPERIMENTAL
Intervention: Reirradiation with various doses: 8 Gy single-dose, 5×3 Gy, 2×8 Gy, 5×4 Gy, single doses of 7 and 4 Gy.
Number of subjects: 579
Study 21295881 — intervention group
Group type: EXPERIMENTAL
Intervention: Reirradiation (various doses)
Number of subjects: 579
Study 18930646 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 mcg)
Number of subjects: 16
Study 18930646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18930646 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 16
Study 16750294 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (Botulinum type A toxin)
Number of subjects: 0
Study 16750294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 14751650 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat 10 mg
Number of subjects: 25302
Study 14751650 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 5 mg
Number of subjects: 25302
Study 11148859 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Zoltrix)
Number of subjects: 24
Study 11148859 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 24
Study 9068312 — intervention group
Group type: EXPERIMENTAL
Intervention: One hour amphotericin B infusion
Number of subjects: 0
Study 9068312 — intervention group
Group type: COMPARATOR
Intervention: Four hour amphotericin B infusion
Number of subjects: 0
Study 8453190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 1000
Study 8453190 — intervention group
Group type: COMPARATOR
Intervention: Broadband ultrasound attenuation (BUA)
Number of subjects: 1000
Study 3010692 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 9
Study 3010692 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 9
Study 3010692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3010692 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg/kg) with Propranolol
Number of subjects: 9
Study 3010692 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg/kg) with Atenolol
Number of subjects: 9
Study 28960513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling both back and head (neck)
Number of subjects: 16
Study 28960513 — intervention group
Group type: EXPERIMENTAL
Intervention: Back cooling alone
Number of subjects: 16
Study 28960513 — intervention group
Group type: EXPERIMENTAL
Intervention: Head (neck) cooling alone
Number of subjects: 16
Study 28960513 — intervention group
Group type: COMPARATOR
Intervention: No cooling (control)
Number of subjects: 16
Study 27217459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative chemotherapy with 1,200 cGy TBI
Number of subjects: 101
Study 27217459 — intervention group
Group type: COMPARATOR
Intervention: Nonmyeloablative chemotherapy without TBI
Number of subjects: 101
Study 24939366 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial uncinectomy
Number of subjects: 25
Study 24939366 — intervention group
Group type: COMPARATOR
Intervention: Total uncinectomy
Number of subjects: 25
Study 23526959 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment every three months for 21 months
Number of subjects: 4004
Study 23526959 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment every three months for 21 months
Number of subjects: 4004
Study 23526959 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 4004
Study 21169142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.2 μg/kg per minute)
Number of subjects: 42
Study 21169142 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (2 μg/kg per minute)
Number of subjects: 42
Study 21169142 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 42
Study 17499419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 100
Study 17499419 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 100
Study 15676129 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hospitalization (HH) program
Number of subjects: 40
Study 15676129 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospitalization
Number of subjects: 40
Study 12363466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined passive active immunisation with human specific Hepatitis B immunoglobulin (HEPABIG‐VHB Pharmaceuticals) and Hepatitis B vaccine (arm I)
Number of subjects: 60
Study 12363466 — intervention group
Group type: COMPARATOR
Intervention: Active immunisation along with interferon (arm II)
Number of subjects: 60
Study 12363466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined passive active immunisation with human specific Hepatitis B immunoglobulin (HEPABIG‐VHB Pharmaceuticals)
Number of subjects: 60
Study 12363466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined passive active prophylaxis
Number of subjects: 60
Study 10364782 — intervention group
Group type: EXPERIMENTAL
Intervention: 22.5% branched chain amino acids + 20% LCT
Number of subjects: 62
Study 10364782 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% branched chain amino acids + 20% LCT
Number of subjects: 62
Study 10364782 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% branched chain amino acids + 20% MCT/LCT
Number of subjects: 62
Study 10364782 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard solution)
Number of subjects: 62
Study 8529068 — intervention group
Group type: COMPARATOR
Intervention: Dopamine 1 microgram/kg/min
Number of subjects: 10
Study 8529068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 1 microgram/kg/min + Domperidone 30 mg
Number of subjects: 10
Study 8529068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 3 micrograms/kg/min
Number of subjects: 10
Study 8529068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 1 and 3 micrograms/kg/min
Number of subjects: 10
Study 8529068 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 2406848 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-hydroxybutyrate (GHB)
Number of subjects: 0
Study 2406848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7022973 — intervention group
Group type: EXPERIMENTAL
Intervention: E7H7 (ethambutol 15 mg/kg plus isoniazid 400 mg daily)
Number of subjects: 424
Study 7022973 — intervention group
Group type: EXPERIMENTAL
Intervention: E2H2 (ethambutol 45 mg/kg plus isoniazid 15 mg/kg twice a week)
Number of subjects: 424
Study 7022973 — intervention group
Group type: EXPERIMENTAL
Intervention: E1H2 (ethambutol 90 mg/kg plus isoniazid 15 mg/kg once a week plus isoniazid 15 mg/kg mid-way between the weekly doses)
Number of subjects: 424
Study 7022973 — intervention group
Group type: EXPERIMENTAL
Intervention: E1H1 (ethambutol 90 mg/kg plus isoniazid 15 mg/kg once a week)
Number of subjects: 424
Study 7022973 — intervention group
Group type: EXPERIMENTAL
Intervention: E7H7
Number of subjects: 424
Study 7022973 — intervention group
Group type: EXPERIMENTAL
Intervention: E2H2
Number of subjects: 424
Study 7022973 — intervention group
Group type: EXPERIMENTAL
Intervention: E1H2
Number of subjects: 424
Study 7022973 — intervention group
Group type: EXPERIMENTAL
Intervention: E1H1
Number of subjects: 424
Study 31092115 — intervention group
Group type: EXPERIMENTAL
Intervention: C8 Health Project participation
Number of subjects: 1500
Study 30559477 — intervention group
Group type: EXPERIMENTAL
Intervention: Inference process model for subjective valuation
Number of subjects: 0
Study 29231503 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (acupuncture and western medication)
Number of subjects: 120
Study 29231503 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120
Study 29231503 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medication (ribavirin granules 10 mg/kg a day, three times a day for 3 days)
Number of subjects: 120
Study 26387933 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 26387933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0
Study 22796064 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean/MCT/olive/fish emulsion (SMOFlipid, n = 34)
Number of subjects: 73
Study 22796064 — intervention group
Group type: COMPARATOR
Intervention: Soybean emulsion (Intralipid, control n = 39)
Number of subjects: 73
Study 21476029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal pouch-rectal muscle sheath anastomosis
Number of subjects: 22
Study 21476029 — intervention group
Group type: COMPARATOR
Intervention: Ileal pouch-anal anastomosis
Number of subjects: 22
Study 18424129 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐mIBG positive metastatic disease after four chemotherapy cycles
Number of subjects: 113
Study 18424129 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐mIBG positive metastatic disease after six chemotherapy cycles
Number of subjects: 113
Study 17065540 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention
Number of subjects: 0
Study 17065540 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12836088 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Reliefband
Number of subjects: 49
Study 11218246 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b (IFN-alpha2b) treatment
Number of subjects: 88
Study 11218246 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 88
Study 9299856 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole (group B)
Number of subjects: 72
Study 9299856 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange and steroids without antiplatelet agents (group A)
Number of subjects: 72
Study 9299856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine maintenance therapy (after disease remission)
Number of subjects: 72
Study 8467430 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (100 mg, single oral dose)
Number of subjects: 14
Study 8467430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3537251 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ng/kg/day ethinyl estradiol
Number of subjects: 16
Study 3537251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30292589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (10-20 μg daily subcutaneous injection)
Number of subjects: 6068
Study 30292589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 6068
Study 30292589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6068
Study 26848931 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal micronutrient supplementation during pregnancy
Number of subjects: 0
Study 24893311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral bladder tumor resection
Number of subjects: 8188
Study 24893311 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral bladder tumor resection
Number of subjects: 8188
Study 22943927 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 67
Study 22943927 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 67
Study 22943927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (fenofibrate and atorvastatin)
Number of subjects: 67
Study 22943927 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic lifestyle change
Number of subjects: 67
Study 20730858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (EVICEL(™) Fibrin Sealant (Human))
Number of subjects: 147
Study 20730858 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 147
Study 18812609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CNTO 528
Number of subjects: 44
Study 18812609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16023466 — intervention group
Group type: EXPERIMENTAL
Intervention: Plugs made out of Microcell Puff Lite or Plastazote Medium, 40 mm width, placed at peak pressure sites
Number of subjects: 5
Study 16023466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure based placement, 40 x 20 mm, Plastazote Medium
Number of subjects: 5
Study 16023466 — intervention group
Group type: COMPARATOR
Intervention: Control midsoles manufactured using Microcell Puff
Number of subjects: 5
Study 14761128 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 0
Study 14761128 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin
Number of subjects: 0
Study 10665890 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication of the self‐management program developed at a university medical center
Number of subjects: 0
Study 10665890 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified version of the self‐management program including only the core elements
Number of subjects: 0
Study 10665890 — intervention group
Group type: COMPARATOR
Intervention: Usual-care program
Number of subjects: 0
Study 8909669 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine (0.15 mg/kg)
Number of subjects: 59
Study 8909669 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine (0.15 mg/kg)
Number of subjects: 59
Study 2483556 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiation and combination of bleomycin and 5-fluorouracil (5-FU)
Number of subjects: 74